Evidence map›Paper›PMID 34085581›Full record

Trial reportJournal of attention disorders2022

Clinically Meaningful Improvements in Early Morning and Late Afternoon/Evening Functional Impairment in Children with ADHD Treated with Delayed-Release and Extended-Release Methylphenidate.

Timothy E Wilens, Stephen V Faraone, Paul G Hammerness, Steven R Pliszka, Cassandra L Uchida, Norberto J DeSousa, Floyd R Sallee, Bev Incledon, Jeffrey H Newcorn

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Journal of attention disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02520388 (Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02520388 phase3completednot on this map

Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD

TypeinterventionalSponsorIronshore Pharmaceuticals and Development, IncRan2015 to 2016Enrolled163ConditionsAttention Deficit Hyperactivity DisorderArmsHLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Timothy E WilensMassachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-5749-8503
Stephen V FaraoneSUNY Upstate Medical University, Syracuse, NY, USA.ORCID 0000-0002-9217-3982
Paul G HammernessHarvard Medical School, Boston, MA, USA.
Steven R PliszkaThe University of Texas Health Science Center at San Antonio, TX, USA.
Cassandra L UchidaHighland Therapeutics Inc., Toronto, ON, Canada.ORCID 0000-0002-6537-4092
Norberto J DeSousaIronshore Pharmaceuticals & Development, Inc., Camana Bay, Grand Cayman, Cayman Islands.
Floyd R SalleeIronshore Pharmaceuticals Inc., Durham, NC, USA.
Bev IncledonIronshore Pharmaceuticals & Development, Inc., Camana Bay, Grand Cayman, Cayman Islands.
Jeffrey H NewcornMount Sinai Medical Center, New York, NY, USA.
Boston Children's Hospital · USHarvard University · USMount Sinai Medical Center · USSUNY Upstate Medical University · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe Before School Functioning Questionnaire and Parent Rating of Evening and Morning Behavior-Revised assess early morning (BSFQ, PREMB-R AM subscale) and late afternoon/evening (PREMB-R PM subscale) functional impairment in children with ADHD. Clinically meaningful improvements were identified and applied to a trial of delayed-release and extended-release methylphenidate (DR/ER-MPH) in children with ADHD (NCT02520388) to determine if the statistically-determined improvements in functional impairment were also clinically meaningful.

methodClinically meaningful improvements in BSFQ/PREMB-R were established post hoc by receiver operating characteristics curves, using anchors of Clinical Global Impression-Improvement (CGI-I) = 1 and CGI-I ≤ 2. Percentages of participants achieving these thresholds were calculated.

resultsThresholds for CGI-I = 1/CGI-I ≤ 2, respectively, were 27/20 (BSFQ), 5/3 (PREMB-R AM), and 9/5 (PREMB-R PM)-point decreases. More children achieved clinically meaningful improvements with DR/ER-MPH versus placebo (all

conclusionDR/ER-MPH increased proportions of children achieving clinically meaningful improvements in BSFQ and PREMB-R.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateChildDelayed-Action PreparationsDouble-Blind MethodHumansTreatment OutcomeCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateADHDBSFQfunctional impairmentmethylphenidatePREMB-R

Identifiers

PMID34085581
PMCPMC8785267
OpenAlexW3165295054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.